The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

(Bloomberg) -- Sales of GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited demand for the shots in the US. Arexvy, a vaccine for respiratory ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...